US 12,221,486 B2
Caninized human antibodies to human IL-4R alpha
Mohamad Morsey, Omaha, NE (US); and Yuanzheng Zhang, Edison, NJ (US)
Assigned to INTERVET INC., Rahway, NJ (US)
Filed by Intervet Inc., Madison, NJ (US)
Filed on Jun. 30, 2021, as Appl. No. 17/363,749.
Application 17/363,749 is a division of application No. 16/061,712, granted, now 11,091,556, previously published as PCT/EP2016/081138, filed on Dec. 15, 2016.
Claims priority of provisional application 62/401,368, filed on Sep. 29, 2016.
Claims priority of provisional application 62/269,486, filed on Dec. 18, 2015.
Prior Publication US 2022/0056143 A1, Feb. 24, 2022
Int. Cl. C12N 15/13 (2006.01); A61P 17/00 (2006.01); C07K 16/28 (2006.01)
CPC C07K 16/2866 (2013.01) [A61P 17/00 (2018.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/53 (2013.01); C07K 2317/71 (2013.01); C07K 2317/73 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01)] 14 Claims
 
1. A nucleic acid that encodes a canine kappa light chain of a caninized antibody that specifically binds interleukin-4 receptor alpha (IL-4Rα); wherein the canine kappa light chain comprises three light chain complementary determining regions (CDRs): CDR light 1 (CDRL1), CDR light 2 (CDRL2), and CDR light 3 (CDRL3); and
(a) wherein CDRL1 comprises the amino acid sequence of SEQ ID NO: 43;
(b) wherein CDRL2 comprises the amino acid sequence comprising SEQ ID NO: 44; and
(c) wherein CDRL3 comprises the amino acid sequence of SEQ ID NO: 45.